Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea

Journal of Drugs in Dermatology

Volumn 9, Issue 6, 2010, Pages 607-613

  Del Rosso, James Q ^a   Bruce, Suzanne ^b   Jarratt, Michael ^c   Menter, Alan ^d   Staedtler, Gerald ^e  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b Suzanne Bruce and Associates   (United States)

^c DermResearch Inc   (United States)

^d BAYLOR RESEARCH INSTITUTE   (United States)

^e Intendis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; CYTOKINE; DOXYCYCLINE; METRONIDAZOLE; DICARBOXYLIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL PAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAPULOPUSTULAR ROSACEA; PHASE 4 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SINGLE BLIND PROCEDURE; SKIN CARE; URTICARIA; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GEL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; DICARBOXYLIC ACIDS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; GELS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ROSACEA;

EID: 77955877768     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. National Rosacea Society Web site. Information for patients. Available at http://www.rosacea.org/patients/index.php. Accessed February 5, 2010.
2. Yentzer BA, Fleischer AB Jr. Changes in rosacea comorbidities and treatment utilization over time. J Drugs Dermatol. Submitted for publication.
3. International Rosacea Foundation website. Symptoms of rosacea. Available at http://www.internationalrosaceafoundation.org/symptoms.php. Accessed February 5, 2010.
4. Yamasaki K, Gallo RL. The molecular biology of rosacea. J Dermatolog Sci. 2009;55:77-81.
5. Buechner SA. Rosacea: An update. Dermatology. 2005;210(2):100-108. (Pubitemid 40463198)
6. Yamasaki K, Gallo R. Azelaic acid (AzA) gel 15% decreases kallikrein 5 in epidermal keratinocytes, critical elements in production of cathelicidin and the pathogenesis of rosacea. Presented at the 28th Anniversary Fall Clinical Dermatology Conference; October 15-18, 2009; Las Vegas, NV.
7. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. (Pubitemid 47222043)
8. Yamasaki K, Gallo R. Azelaic acid (AzA) gel 15% decreases kallikrein 5 in epidermal keratinocytes, critical elements in production of cathelicidin and the pathogenesis of rosacea. Presented at the 68th Annual Meeting of the American Academy of Dermatology; March 5-9, 2010; Miami Beach, FL.
9. Del Rosso JQ. Adjunctive skin care in the management of rosacea: Cleansers, moisturizers, and photoprotectants. Cutis. 2005;75(Suppl 3): 17-21. (Pubitemid 40521803)
10. Feldman SR, Hollar CB, Gupta AK, Fleischer AB Jr. Women commonly seek care for rosacea: Dermatologists frequently provide the care. Cutis. 2001;68(2):156-160. (Pubitemid 33757349)
11. Draelos Z, Kayne AL. Implications of azelaic acid's multiple mechanisms of action: Therapeutic versatility. Presented at: American Academy of Dermatology 66th Annual Meeting; February 1-5, 2008; San Antonio, TX.
12. Passi S. Pharmacology and pharmacokinetics of AzA. Rev Contemp Pharmacother. 1993;4:441-447.
13. Narayanan S, Hünerbein A, Getie M, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59(8):1125-1130. (Pubitemid 47265360)
14. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther. 2001:18(6):237-243. (Pubitemid 34117279)
15. American Acne and Rosacea Society. Rosacea Medical Management Guidelines. Paper presented at the 26th Anniversary Fall Clinical Dermatology Conference; October 18-21, 2007; Las Vegas, NV.
16. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639-648.
17. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541-546.
18. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-845. (Pubitemid 36706214)
19. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3-11. (Pubitemid 43723532)
20. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: Results of a randomized trial. Arch Dermatol. 2003;139(11):1444-1450. (Pubitemid 37433134)
21. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. (Pubitemid 46561002)
22. McDonnell JK, Tomecki KJ. Rosacea: An update. Cleve Clin J Med. 2000;67(8):587-590. (Pubitemid 30618552)
23. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc). 2007;43(1):27-34. (Pubitemid 46448835)